Investigating rifampicin resistance in Staphylococcus aureus during latent tuberculosis treatment
Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis
This study is testing whether people being treated for latent tuberculosis with rifampicin or isoniazid are at risk of developing resistance to rifampicin in Staphylococcus aureus and if this resistance can spread to others in their households.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Region Skane Academic / other |
| Locations | 1 site (Malmö) |
| Trial ID | NCT05073926 on ClinicalTrials.gov |
What this trial studies
This observational study examines the risk of developing rifampicin resistance in Staphylococcus aureus among patients undergoing treatment for latent tuberculosis with either rifampicin or isoniazid. Participants will provide swab samples from various body sites before, during, and after treatment to monitor for resistance mutations. The study also aims to assess the potential transmission of rifampicin-resistant S. aureus among household contacts of affected individuals. By utilizing whole genome sequencing, the research will analyze the genetic changes associated with resistance over time.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with latent tuberculosis who are prescribed either 4 months of rifampicin or 6-9 months of isoniazid.
Not a fit: Patients who are not diagnosed with latent tuberculosis or those who do not meet the treatment criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help inform safer treatment protocols for latent tuberculosis that minimize the risk of developing antibiotic resistance.
How similar studies have performed: While the approach of studying rifampicin resistance in S. aureus is not widely tested, similar studies on antibiotic resistance have shown significant insights into microbial behavior.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed with latent tuberculosis * prescribed either 4 months rifampicin or 6-9 months isoniazide * informed consent Exclusion Criteria: * none
Where this trial is running
Malmö
- Skåne University Hospital — Malmö, Sweden (Recruiting)
Study contacts
- Study coordinator: Anton Reepalu, PhD
- Email: anton.reepalu@med.lu.se
- Phone: +4640337818
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.